Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

Transgene to Participate in HTID Conference and Investor Access Forum in Paris

investor events

Published 5 September 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release

Transgene — Preclinical Proof of Concept Data of Oncolytic Virus TG6050 published in JITC

TG6050

Published 27 August 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release, TG6050-en

Transgene strengthens its balance sheet via equity conversion of current account advance from TSGH

current account advance

Published 30 July 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release

Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024

BT-001 ESMO 2024

Published 22 July 2024
Categorized as 2024, BT-001, categorie-orpheline, dates, dates, Press release

Transgene – First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer

TG4050

Published 3 June 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release, TG4050

Transgene’s Combined General Meeting of May 15, 2024

General meeting 2024

Published 15 May 2024
Categorized as 2024, Press release

Transgene provides business and financial update for Q1 2024

Financial update Q1 2024

Published 14 May 2024
Categorized as 2024, Press release

Availability of of Preparatory Documents for the Combined General Meeting of May 15, 2024

Shareholders’ meeting 2024

Published 24 April 2024
Categorized as 2024, Press release

Availability of Transgene’s 2023 Universal Registration Document

URD 2023

Published 11 April 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release

Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024

TG4050 AACR 2024

Published 9 April 2024
Categorized as 2024, Myvac, Press release, TG4050

Posts pagination

Newer posts Page 1 … Page 7 … Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu